Filters

Anti-HIF3 alpha (Polyclonal), ALEXA Fluor 594

Anti-HIF3 alpha (Polyclonal), ALEXA Fluor 594 size: 100 microliters 489

Supplier BIOSS POLYCLONAL ANTIBODIES
Price 489
Size 100 microliters
Contact us Ask Component cell markers and DNA bp. markers are genetic markerser genes or DNA sequenceswith selection audit
TypeConjugated Primary Antibody
Conjugated with 594, ALEXA FLUOR®
Host organismRabbit (Oryctolagus cuniculus)
Target Protein/PeptideH3 alpha
SpecificityThis antibody reacts specifically with HIF3 alpha
ModificationNo modification has been applied to this antibody
Modification siteNone
ClonalityPolyclonal Antibody
ClonePolyclonal Antibodies
Concentration1ug per 1ul
Subcellular locations Nucleus, Cytoplasm
Antigen SourceKLH conjugated synthetic peptide derived from human HIF3 alpha
Gene ID64344
Swiss ProtQ9Y2N7
ApplicationsIF(IHC-P)
Applications with corresponding dilutionsIF(IHC-P)(1:50-200)
Cross reactive species Mouse (Mus musculus), Rat (Rattus norvegicus), Human (Homo sapiens)
Cross Reactive Species details However, note that due to limited knowledge it is impossible to predict with 100% guarantee that the antibody does not corss react with any other species, No significant cross reactivity has been observed for this antibody for the tested species
Background information Binds to core DNA sequence 5'-TACGTG-3' within the hypoxia response element (HRE) of target gene promoters, Conversely, Functions as an inhibitor of angiogenesis in the cornea (By similarity), Hypoxia induces down-regulation of isoform 4, Isoform 4 attenuates the binding of HIF1A to hypoxia-responsive elements (HRE), Isoform 4 has a dominant-negative function of inactivating HIF1A-mediated transcription, Isoform 4 may be a negative regulator of hypoxia-inducible gene expression in the kidney and may be involved in renal tumorigenesis, Suppresses hypoxia-inducible expression of HIF1A and EPAS1, The complex HIF3A-ARNT activates the transcription of reporter genes driven by HRE, leading to activation of HIF1A in hypoxia, the expression of isoform 4 increases and thereby secure an inhibition of HIF1A activity, thus inhibiting HRE-driven transcription, upon restoring normoxia, Involved in adaptive response to hypoxia
Purification methodPurified by Protein A
Storage 50% glycerol and 0, Store at 4°, 09% sodium azide, C for 12 months, Water buffered solution containing 100ug/ml BSA
Excitation emission590nm/617nm
Synonyms Basic-helix-loop-helix-PAS protein MOP7, Class E basic helix-loop-helix protein 17, HIF-3-alpha, HIF-3A, HIF3-alpha, HIF3-alpha-1, HIF3A, Hypoxia-inducible factor 3-alpha, Inhibitory PAS domain protein, MOP7, Member of PAS protein 7, PAS domain-containing protein 7, PASD7, bHLHe17, IPAS
Also known asHIF3 alpha Polyclonal Antibody
Other nameAnti-HIF3 alpha Polyclonal
Advisory For antibodies that are in liquid form or reconstituted lyophilized antibodies small amounts could become entrapped on the seal or the walls of the tube, Prior to use briefly centrifuge the vial to gather all the solution on the bottom, specificity and sensitivity, thus reducing its reactivity, Avoid freeze/thaw cycles as they may denaturate the polypeptide chains of the antibody
PropertiesFor facs or microscopy Alexa 1 conjugate
ConjugationAlexa Fluor
GroupPolyclonals and antibodies
About The advantage is that there are more epitopes available in a polyclonal antiserum to detect the proteins than in monoclonal sera, immunohistochemistry on frozen slices or parrafin fixed tissues, Polyclonals can be used for Western blot
Gene targetHIF3 alpha
Short nameAnti-HIF3 alpha (Polyclonal) Fluor 594
Technique Pabs are a collection of immunoglobulin , Polyclonal antibodies , each identifying a different , whereas , (pAbs) are mostly rabbit or goat , B cells, Polyclonal, antibodies , antigen, come from a single N cell lineage, epitope, molecules that react against a specific , monoclonal antibodies , that are secreted by different 
LabelALEXA
Alternative name ALEXA Fluor 594, antibody to-HIF3 a (polyclonal)
Alternative techniquepolyclonals

Similar products

Subscribe to our Newsletter